Cartesian Therapeutics (RNAC) Competitors $13.37 +1.19 (+9.77%) Closing price 03:58 PM EasternExtended Trading$13.44 +0.08 (+0.56%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. PHVS, CVAC, CDTX, PAHC, CALT, AUPH, ELVN, GPCR, BGM, and PRAXShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Pharvaris (PHVS), CureVac (CVAC), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), BGM Group (BGM), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors Pharvaris CureVac Cidara Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Enliven Therapeutics Structure Therapeutics BGM Group Praxis Precision Medicines Cartesian Therapeutics (NASDAQ:RNAC) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment. Which has stronger valuation and earnings, RNAC or PHVS? Cartesian Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M8.92-$77.42M-$52.83-0.25PharvarisN/AN/A-$145.24M-$3.01-6.92 Does the media refer more to RNAC or PHVS? In the previous week, Pharvaris had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Pharvaris and 0 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.00 equaled Pharvaris'average media sentiment score. Company Overall Sentiment Cartesian Therapeutics Neutral Pharvaris Neutral Is RNAC or PHVS more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -7.01% Pharvaris N/A -54.02%-50.36% Do analysts rate RNAC or PHVS? Cartesian Therapeutics currently has a consensus price target of $40.00, suggesting a potential upside of 199.18%. Pharvaris has a consensus price target of $36.20, suggesting a potential upside of 73.70%. Given Cartesian Therapeutics' higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in RNAC or PHVS? 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, RNAC or PHVS? Cartesian Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.82, meaning that its stock price is 382% less volatile than the S&P 500. SummaryCartesian Therapeutics beats Pharvaris on 9 of the 12 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$346.95M$3.04B$5.66B$9.45BDividend YieldN/A2.49%4.01%4.02%P/E Ratio-0.2521.3928.0720.12Price / Sales8.92275.08417.5199.64Price / CashN/A41.6635.9658.29Price / Book-49.528.188.555.81Net Income-$77.42M-$55.10M$3.24B$258.18M7 Day Performance0.75%7.63%4.86%3.98%1 Month Performance36.01%21.73%13.00%14.81%1 Year Performance-21.40%6.45%35.57%19.30% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.6869 of 5 stars$13.37+9.8%$40.00+199.2%-27.7%$346.95M$38.91M-0.2564PHVSPharvaris1.1562 of 5 stars$23.84+2.5%$36.20+51.8%+24.3%$1.22BN/A-7.9230News CoverageGap DownCVACCureVac4.1073 of 5 stars$5.40+0.2%$6.83+26.5%+43.3%$1.21B$579.18M5.87880CDTXCidara Therapeutics3.5735 of 5 stars$57.05-4.9%$57.29+0.4%+424.1%$1.21B$302K-1.9490Gap UpHigh Trading VolumePAHCPhibro Animal Health4.0717 of 5 stars$29.14-0.9%$24.40-16.3%+54.2%$1.19B$1.19B37.361,940Positive NewsGap UpCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.1877 of 5 stars$8.62-0.1%$11.50+33.4%+63.5%$1.17B$235.13M30.79300Upcoming EarningsELVNEnliven Therapeutics2.7208 of 5 stars$21.87-3.5%$41.20+88.4%-7.8%$1.11BN/A-11.3950News CoverageInsider TradeGPCRStructure Therapeutics3.141 of 5 stars$18.13-5.8%$76.17+320.1%-50.3%$1.10BN/A-20.84136Positive NewsBGMBGM GroupN/A$10.63-5.8%N/AN/A$1.10B$25.10M0.00298News CoverageHigh Trading VolumePRAXPraxis Precision Medicines2.6236 of 5 stars$55.16+2.4%$94.11+70.6%-3.0%$1.10B$8.55M-5.15110 Related Companies and Tools Related Companies PHVS Competitors CVAC Competitors CDTX Competitors PAHC Competitors CALT Competitors AUPH Competitors ELVN Competitors GPCR Competitors BGM Competitors PRAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAC Stock Alerts